Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.65, missing the estimate of USD -0.5175.

EBIT: As of FY2026 Q2, the actual value is USD -73.13 M.

Financial Highlights (Three Months Ended June 30, 2026 vs. 2025)

Cash and Liquidity

• As of June 30, 2026, cash, cash equivalents, and marketable securities totaled $520.0 million.

Revenue

• Collaboration revenue for the three months ended June 30, 2026, was $0, compared to $4.0 million for the same period in 2025.

Operating Expenses

• Research and development expenses were $59.9 million for the three months ended June 30, 2026, an increase from $40.5 million in the prior year period.
  • This included stock-based compensation expense of $4.2 million in Q2 2026, up from $2.2 million in Q2 2025.
• General and administrative expenses were $18.3 million for the three months ended June 30, 2026, compared to $10.0 million for the same period in 2025.
  • This included stock-based compensation expense of $4.6 million in Q2 2026, up from $3.1 million in Q2 2025.
• Total operating expenses for the three months ended June 30, 2026, were $78.1 million, an increase from $50.5 million in the prior year period.

Operating Loss and Net Loss

• Loss from operations for the three months ended June 30, 2026, was - $78.1 million, compared to - $46.5 million for the same period in 2025.
• Interest income for the three months ended June 30, 2026, was $5.0 million, up from $3.1 million in the prior year period.
• Net loss for the three months ended June 30, 2026, was - $73.1 million, compared to - $43.4 million for the same period in 2025.
• Net loss per share, basic and diluted, was - $0.65 for Q2 2026, compared to - $0.50 for Q2 2025.
• Total share-based compensation expense for the quarter was $8.8 million in 2026, versus $5.3 million in 2025.

Comprehensive Loss

• Comprehensive loss for the three months ended June 30, 2026, was - $73.5 million, compared to - $43.4 million for the same period in 2025.
• Unrealized loss on marketable securities was - $0.3 million in Q2 2026, compared to - $0.021 million in Q2 2025.

Operational Metrics and Pipeline Highlights

Varegacestat

• The U.S. FDA accepted Immunome, Inc.’s New Drug Application (NDA) for varegacestat, setting a PDUFA target action date of April 28, 2027.
• Detailed efficacy and safety results from the Phase 3 RINGSIDE trial demonstrated an 84% reduction in the risk of disease progression or death versus placebo (p<0.0001) and met all key secondary endpoints, including a confirmed objective response rate of 56% versus 9% with placebo (p<0.0001).
• Varegacestat also showed statistically significant improvement in worst pain intensity at week 12, with a clinically significant difference observed as early as week 4.

IM-1021

• The Phase 1 clinical trial is ongoing, with objective responses observed in participants with B-cell lymphoma.

IM-1617

• The first patient was dosed in June 2026 in the Phase 1, first-in-human trial for advanced solid tumors.

IM-3050

• The first patient was dosed in July 2026 in the Phase 1, first-in-human trial for FAP-expressing advanced solid tumors.

Preclinical ADC Pipeline

• Immunome, Inc. expects to submit Investigational New Drug (IND) applications for IM-1340 and IM-1335 in mid- and late 2026, respectively.

Outlook / Guidance

Immunome, Inc. expects its current cash position to fund operations into 2028. The company plans to submit a Marketing Authorization Application for varegacestat to the European Medicines Agency by the end of 2026. Additionally, Immunome, Inc. anticipates presenting initial lymphoma data for IM-1021 in 2026 and submitting INDs for IM-1340 and IM-1335 in mid- and late 2026, respectively.